ABSTRACT: Circadian rhythms are essential for controlling the cell cycle, cellular proliferation, and apoptosis, and hence, are tightly linked to cell fate. Disruption of circadian rhythms has been shown to trigger various pathological developments, including cancer. Several recent studies have used a variety of small molecules to affect circadian oscillations, however, their concomitant cellular effects were not assessed. Here, we use five molecules, grouped into direct versus indirect effectors of the circadian clock, to modulate periods in a human osteosarcoma cell line (U2OS), and determined their influences on cellular behaviors, including motility and colony formation. Luciferase reporters, whose expression were driven via Bmal1-and Per2-promoters (positive and negative protein components of the core clock), were used to facilitate the visualization and quantitative analysis of circadian oscillations. We show that all molecules significantly increase or decrease the circadian periods of Bmal1 and Per2 in a dosedependent manner, but period length does not correlate with the extent of cell migration or proliferation. We observed that only molecules that affected circadian oscillations to a greater extent showed significant influence on cell functions (e.g. motility and colony formation).
proteins aryl hydrocarbon receptor nuclear translocator-like protein 1 (ARNTL/BMAL1) and circadian locomotor output cycles kaput (CLOCK) heterodimerize in the morning and bind to the E-box promoter, which initiates the expression of Period (Per) and Cryptochrome (Cry). PER and CRY accumulate in the evening and form a heterodimer, which translocates back into the nucleus and inhibits Bmal1 and Clock activity. 18 As a result, the core circadian machinery oscillates with a period of approximately 24 h. In cell culture, intrinsic and self-sustained circadian clocks are persistent even in the absence of external time cues. 19 To synchronize clocks in cultured cells, treatments of high concentration serum 20 or chemical reagents (e.g. dexamethasone 21 or forskolin 22 ) are frequently used.
Circadian rhythmicity is tightly associated with post-translational modifications of clock proteins. 23 Phosphorylation of most clock proteins occurs in a rhythmic manner; thus, alteration of clock protein phosphorylation can result in changes to circadian periods. 24 Genetic manipulations of the post-translational regulators of clock proteins have been shown to affect circadian functions and periodicity. [24] [25] However, conventional genetic approaches also result in fatality, pleiotropy, and functional redundancy. Alternatively, chemical modulation of these regulators via small molecules can reversibly manipulate clock functions in time-and dosedependent manners.
therapeutic potential as well. It has been recently reported by Sulli et al. that SR9009 and SR9011, two agonists of REV-ERBs (secondary clock components), have potent anti-cancer effects in various cancer cell lines, and no toxicity in normal cells or tissues. 33 Oshima et al.
discovered GO289, which regulates circadian rhythms via inhibition of CK2, finding that it suppressed cancer cell proliferation in a cell type-dependent manner. 30a But, among work published, the biological and circadian effects of most small molecules, including those studied here, have not been addressed concurrently, nor have they been studied in similar systems using the same modes of analysis. Hence, we present a systematic assessment, whereby we have thoroughly evaluated a small panel of these molecules, also addressing whether concentration ranges resulting in circadian effects yield cellular changes and vice-versa.
In this study, we used five small molecules to affect circadian period (the time interval for completing one oscillation cycle), and assessed concomitant changes to the oncogenic traits of cancer cells. Among the selected compounds, two, KL001 27 and PF-670462, 34 result in direct effects on circadian proteins and the other three, SP600125, 35 Chir99021, and Etoposide, 36 target entities that regulate core circadian proteins in a post-translational manner (Fig. 1) . A human bone osteosarcoma epithelial cell line, U2OS, was separately transfected with Bmal1:luc and 6 between Chir99021 and Etoposide treatments, which both decreased periods, but while Chir99021 suppressed cell migration, Etoposide had no effect. Our data suggest that there may not be a direct connection between circadian rhythms and cancer cell behavior, and the circadian period length may not be a key regulator of cell motility and growth. To confirm whether this is the case, and in further studies using small molecules to affect and study circadian rhythms, molecules directly targeting additional core clock components should be identified and employed. These may be combined with genetic approaches to uncover the molecular details connecting circadian disruptions with cancer development. Colony Formation Assay Cells were suspended in agar and incubated until colonies formed, as previously described. 39 Briefly, 3% 2-Hydroxyethyl Agarose (Sigma) was prepared and stored in a water bath at 45 °C. Cell culture media at 37 °C was used to dilute agarose to 0.6%, and 2 mL was added to each well of a 6-well plate (Nuclon), which was incubated at 4 °C until agar solidified (first, bottom layer). DMSO solutions of molecules were added to 1 mL of 4 x 10 4 cells/mL suspended U2OS cells in warm culture media, followed by addition of 0.6% agarose solution in a 1:1 ratio. 1 mL drug-cell-agarose solution was dispensed per well and incubated at 4 °C for 30 min until the agar layer solidified (second, drug-cell containing layer). Then plates were incubated at 37 °C under 5% CO 2 . A 1 mL feeder layer of 0.3% agarose in culture media containing the small molecules at designated concentrations was added to each well once every 7 days for 4 weeks. When imaging colonies, 1 mL of 0.005% Crystal Violet dye (Fisher) in 20% methanol (Fischer Scientific) was added to wells and incubated on a shaker at rt for 1 h. Wells were then washed 4-6 times with 2 mL ddH 2 O. Eight images were taken per well using a Biotek Citation 3 multi-mode cell imaging reader. Each condition was performed in three biological replicates. Images were stitched using Adobe Illustrator CS6 and colony numbers/sizes were analyzed using ImageJ.
Materials and Methods
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Results and Discussion
Both direct and indirect circadian modulators alter periods in a dose-dependent manner
To evaluate the changes to circadian period caused by the five small molecules used, real-time luminometry assays were performed using human U2OS osteosarcoma cells harboring Table S1 ), within the IC50 range (0.82 to 14 μ M). 27 While perturbation of the FBXL3-CRY regulatory pathway is known to affect circadian period, 41 the other negative clock regulatory pathway, casein kinase I (CKI)-PER, has been linked to period length as well. 24 To evaluate its period effects, we used a CKIδ/ε-selective inhibitor, PF-670462, which also showed a dosedependent period-lengthening effect on Bmal1 in U2OS cells (Figs. 2C, 2D , S3, and Table S1 ).
It has been reported that PF-670462 has an IC50 of 0.55 μ M for CKIε and an IC50 of 0.14 μ M for CKIδ in whole cells. 42 This molecule is proposed to increase circadian periods by specifically inhibiting CKIδ-mediated phosphorylation of PER, but not through CKIε. 34, 42 We also ascertained the molecules' abilities to lengthen the periods of Per2, via U2OS-Per2:luc reporter cells ( Fig. S4 and Table S2 ). As anticipated, both compounds significantly increased the period of Per2; period enhancements were of similar magnitude in both reporter cell lines (Fig. S5) . Table S3 .
The indirect circadian-affecting molecule SP600125 (a JNK inhibitor with a cell-free IC50 of 40 nM for JNK1 and 2, and 90 nM for JNK3) 43 also increased Bmal1 periods in a dosedependent manner (Fig. 3A, 3B , S6, and Table S3 ). However, while we observed that other molecules had similar period enhancements for Bmal1 and Per2, SP600125 had a greater effect on Bmal1 than Per2 periods (Fig. S5, S7 , and S8). It has been shown that activated JNK isomers can phosphorylate BMAL1-CLOCK complexes to regulate the speed and phase of circadian oscillations in cells. 44 Hence, SP600125 may lengthen the period via activation of JNK and through its downstream targets, including c-jun and AP-1, which regulate Per1 and Per2 transcriptional activities and suppress glucocorticoid receptor activity (critical for resetting circadian time). 35, 45 However, evidence also exists that this molecule may alternatively target CKI, which phosphorylates PER. 40 While KL001, PF-670462, and SP600125 all displayed period-lengthening effects, Chir99021 (a GSK3α/β inhibitor with a cell-free IC50 of 10 nM for GSK3α and 6.7 nM for GSK3β) 46 and Etoposide (a TOPII inhibitor with cell type-dependent IC50 ranges from 0.1 to >100 µM) shortened periods. Chir99021 significantly decreased Bmal1 periods in a dosedependent manner (Fig. 3C, 3D , S9, and Table S3 ), however, Etoposide showed significant reduction of period only at the highest concentration tested (Fig. 3E, 3F , S10, and Table S3 ).
Both molecules showed similar effects on Per2 transcription (Fig. S7, S8 ). Chir99021 specifically inhibits GSK3α/β, which prevents phosphorylation of PER2, 47 CRY2, 48 CLOCK, 49 BMAL1, 32 and REV-ERVα. 50 It has been shown that its use in different cell models results in short circadian periods. On the other hand, Etoposide may reduce period by interacting with topoisomerize type II (TOPII), which has been identified as a regulator of Bmal1 transcriptional activity. 51 Taken together, all five small molecules demonstrated an ability to modulate circadian periods of Bmal1 and Per2 in dose-dependent manners not attributable to toxicity (Fig. S11) .
Stabilization of PER and CRY have distinct effects on cancer cell migration. CRY proteins
are generally characterized as tumor suppressors. 52 Ye et al. recently reported a comprehensive analysis of 51 clock and clock-controlled genes across 32 cancer types, finding that 90.2% of them are either up-or down-regulated in at least one cancer. 53 Specifically, CRY2 was found to be down-regulated in most cancers, and its suppression was associated with worse patient survival rates. The cancer suppressive role of CRY2 was also evaluated by Huber et al., whose mechanistic data indicated that CRY2 and FBXL3 cooperatively destabilized c-MYC (a critical oncoprotein for cancer cell proliferation), and disruption of Cry2 may contribute to elevated c-MYC and higher cancer susceptibility in shift-workers and animals. 54 However, Chun et al.
found that a direct CRY inhibitor, KS15, significantly inhibited breast cancer cell proliferation and increased drug responses to chemotherapies. 55 Given that CRY is down-regulated in various cancer types, it was hypothesized that stabilization of CRY via KL001 treatment might lead to reduction of cellular metastatic characteristics. A primary feature of metastasis is the migration of primary cancer cells to other, secondary sites. To assess whether CRY stabilization may influence cancer cell motility, U2OS cells were treated with KL001 and cell migration was evaluated via wound healing assays.
Unexpectedly, our results showed that higher concentrations of KL001 yielded slightly increased cancer cell migration at early time points following treatment (T=6, 12, and 18 h), but resulted in no significant overall (24 h) change (Fig. 4A) . However, it is likely that changes occur in a celldependent manner; Xue et al. used KL001 to impair mitosis and epithelium repair in corneal wound healing. Concurrently, we found that 1.5 μ M PF-670462 treatment significantly inhibited cell motility (Fig. 4B) . Its targets, CKIε and δ , are key regulators for many biological processes, including circadian rhythms, cell cycle, cell adhesion, cytoskeleton construction, and receptorcoupled signal transduction. 57 Meng et al. showed that selective inhibition of CKIδ via PF-670462 stabilized the nuclear localization of endogenous PER2 in both SCN and peripheral cells, indicating that the molecule can act as a PER stabilizer. 34 Our results in Fig. 4 suggest that stabilization of CRY and PER may influence cancer cell migration differently. However, other mechanistic roles of CKI need to be taken into consideration as well. CKI has been implicated in numerous oncogenic signaling networks, including Wnt/β-catenin, p53, PI3K/AKT, NFκB, TGFβ, and Hedgehog pathways, and contradictory evidence has implied that the CKI family may play dual-roles as tumor drivers and suppressors. 57 ,58 While we observed that PF-670462 inhibited osteosarcoma cell migration (Fig. 4B) , the same treatments resulted in promotion of cell proliferation (Fig. S12) . Although different mechanisms for regulating cell proliferation and migration via CKIε/δ activity may exist, we suspect that inhibition of migration via PF-670462 was induced through the TGFβ pathway: it has been shown that this molecule can prevent TGFβ-induced epithelial-mesenchymal transitions that result in enhanced motility.
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Circadian period length may not be correlated with cell migration. Many cellular functions, including cell cycle, proliferation, and migration, are controlled by circadian rhythms, but little is known regarding the association between period length and the rates of these processes. As described above, the two direct circadian modulators, KL001 and PF-670462, resulted in opposite outcomes in their effects on cancer cell migration, although they both increased Bmal1 and Per2 periods in U2OS cells. Differing results were also observed between the two indirect circadian modulators with period-shortening effects: Chir99021 suppressed cell migration in a dose-dependent manner, while Etoposide showed no significant change (Fig. 5) .
As described above, Chir99021 targets GSK3α and β (serine/threonine kinases), which play important roles in many chronic progressive diseases, including diabetes mellitus, neurodegenerative disorders, and cancer. 60 While GSK3β is a key regulator in the Wnt/β-catenin pathway, 61 no data exists to rationalize how activation of β -catenin may result in lower cell motility. However, it has been proposed by Kobayashi et al. that the activities of GSK3α and β are tightly associated with cell migration, and another GSK3 inhibitor suppressed cellular migration through down-regulation of the focal adhesion kinase (FAK)/guanine nucleotide exchange factors (GEF)/Rac1 pathway. 62 Our results may be indicative of this route (Fig. 5A ).
Unlike Chir99021, Etoposide did not affect cell migration (Fig. 5B) or viability (Fig.   S11E ). The target of Etoposide is TOPII, which is known to regulate cell proliferation. There are two TOPII isoenzymes that exist in mammals, TOPII-α and TOPII-β. 63 TOPII-α is a proliferation marker overexpressed in tumor cells, whereas TOPII-β is expressed in proliferating and postmitotic cells. 64 While Etoposide targets both TOPII isoenzymes, the relative contributions of TOPII-α and TOPII-β to its chemotherapeutic effects have yet to be resolved. Additionally, no data exists to demonstrate a connection between TOPII and cell migration. Thus, it is not surprising that Etoposide-mediated inhibition of TOPII in U2OS cells does not affect their migratory behavior. This result also implies that TOPII may not be involved in any pathways that could affect cell motility.
Another indirect circadian modulator, SP600125, increased circadian periods in U2OS cells and also inhibited cell migration (Fig. 5C) . One possible mechanism to explain the inhibition of cellular motility resulting from SP600125 treatment is blockage of the JNK-matrix metalloproteinase (MMP) signaling cascade. 65 The activity of MMPs, especially MMP-2 and -9, has been correlated with cancer cell invasion and migration. elsewhere in this study, we observed that 1.5 μ M PF-670462 significantly increased colony numbers (Fig. 6A) , consistent with 2D proliferation (Fig. S12B) . As mentioned above, the CKI family can play dual roles in many cancer types. 57, 58 Our data provide support for this in that PF-670462 suppresses motility but promotes cell proliferation of osteosarcoma cells. Concurrently, treatment of 7 μ M Etoposide significantly decreased colony size by 75%, from 206±70 μ m to 51±5 μ m (Fig. 6B) . We suspect this was related to inhibition of cancer cell proliferation, not observed with treatment of Chir99021 (Figs. S13A and S13B). Etoposide likely resulted in higher colony numbers on account of its cancer cell and colony growth suppression, which resulted in a lack of aggregation forming clusters (Fig. 6A) . Inhibition of cell proliferation via Etoposide treatment has been observed previously. 66 Additionally, treatment with 10 μ M SP600125 and 3 μ M Chir99021 decreased colony sizes by 59% and 32%, respectively, but had no effects on numbers of colonies relative to non-treated controls. This data indicates that Chir99021 and SP600125 may inhibit cell proliferation in a 3D environment (Fig. 6 ), but not in 2D monolayer cultures (Figs. S13B and S13C). This is not surprising given that it is wellestablished that cells in two-versus three-dimensions may respond differently to drugs, 67 underscoring the importance of this type of assessment.
Conclusion
Disruption of circadian rhythms has been shown to elicit pathological development associated with cancer and other diseases. While many small molecules have been developed to modulate circadian rhythms, a systematic evaluation that uses the same concentration ranges in a parallel comparison of their effects on cellular and oncogenic characteristics is lacking. Here, five small molecules were used to modulate circadian period (e.g. increase or decrease the period of the circadian cycle) in the human osteosarcoma U2OS cell line. We found that they can influence periods and cancer cell migration, proliferation, and tumor formation to varying extents. KL001 and PF-670462 are two direct circadian modulators, which were previously shown to stabilize CRY and PER respectively. While both significantly increased the periods of Bmal1 and Per2 in U2OS cells, they exhibited opposing effects on cell migration. At T=6, 12, and 18 h, KL001 promoted cancer cell migration, but had no effects on cell proliferation or colony formation. Conversely, PF-670462 inhibited cell migration at the highest concentration tested, and enhanced cell proliferation and colony numbers.
SP600125, Chir99021, and Etoposide are three indirect circadian modulators, all of which significantly altered the periods of Bmal1 and Per2 in U2OS cells. Treatment with SP600125 increased periods, while Chir99021 and Etoposide resulted in decreases. In evaluating their effects on cancer cell behaviors, we hypothesized that we would observe opposing trends between period-lengthening and period-shortening groups in altering cell migration and colony formation. However, we found that both SP600125 and Chir99021 treatments inhibited cell migration, and resulted in diminished colony sizes. On the other hand, Etoposide showed no effect on cell migration but significantly reduced cell proliferation and colony size, which may be attributed to inhibition of TOPII, a key enzyme in DNA cleavage/ligation and cell proliferation regulation, likely not involved in cell migratory pathways. These data indicate that circadian period length may not be correlated with cell growth and migration.
Our data suggest that directly targeting circadian proteins or inducing circadian period effects may not be sufficient to modulate cancerous phenotypes. It is plausible that non-circadian pathways have a greater influence on cellular behavior. However, based on our results, it may also be possible that cellular effects are only observed upon significant deviation from the twenty-four hour cycle. There is no shortage of work to be done in this area, including assessment of other circadian alterations, including amplitude and phase, use of additional small molecules directly targeting circadian proteins that have greater effects on period, utilization of next generation sequencing (NGS) methods to further assess connections between small
